Combination of pembrolizumab and abemaciclib for the treatment of cancer

A method of treating breast cancer, comprising administering to a patient 200 mg of an anti-PD-1 antibody or antigen binding fragment thereof comprising three light chain CDRs (CDRL1, CDRL2 and CDRL3) and three heavy chain CDRs (CDRH1, CDRH2, and CDRH3), wherein CDRL1 comprises the amino acid sequence set forth in SEQ ID NO:5, CDRL2 comprises the amino acid sequence set forth in SEQ ID NO:6 , CDRL3 comprises the amino acid sequence set forth in SEQ ID NO:7, CDRH1 comprises the amino acid sequence set forth in SEQ ID NO:8, CDRH2 comprises the amino acid sequence set forth in SEQ ID NO:9, and CDRH3 comprises the amino acid sequence set forth in SEQ ID NO:10 in combination with 150 mg of abemaciclib or a pharmaceutically acceptable salt thereof wherein initial administration of the abemaciclib or the salt thereof is administered to the patient without the antibody or the antigen binding fragment thereof for at least 24 hours and the abemaciclib or the salt thereof is then administered to the patient in combination with the antibody or the antigen binding fragment thereof.

(canceled)

(canceled)

(canceled)

(canceled)

A method of treating non-small cell lung cancer, comprising administering to a patient 200 mg of an anti-PD-1 antibody or antigen binding fragment thereof comprising three light chain CDRs (CDRL1, CDRL2 and CDRL3) and three heavy chain CDRs (CDRH1, CDRH2, and CDRH3), wherein CDRL1 comprises the amino acid sequence set forth in SEQ ID NO:5, CDRL2 comprises the amino acid sequence set forth in SEQ ID NO:6, CDRL3 comprises the amino acid sequence set forth in SEQ ID NO:7, CDRH1 comprises the amino acid sequence set forth in SEQ ID NO:8, CDRH2 comprises the amino acid sequence set forth in SEQ ID NO:9, and CDRH3 comprises the amino acid sequence set forth in SEQ ID NO:10 on day 1 of a 21-day cycle and 150 mg of abemaciclib or a pharmaceutically acceptable salt thereof twice daily on days 1-21 of the 21-day cycle.

A method of treating non-small cell lung cancer, comprising administering to a patient 200 mg of an anti-PD-1 antibody or antigen binding fragment thereof comprising three light chain CDRs (CDRL1, CDRL2 and CDRL3) and three heavy chain CDRs (CDRH1, CDRH2, and CDRH3), wherein CDRL1 comprises the amino acid sequence set forth in SEQ ID NO:5, CDRL2 comprises the amino acid sequence set forth in SEQ ID NO:6, CDRL3 comprises the amino acid sequence set forth in SEQ ID NO:7, CDRH1 comprises the amino acid sequence set forth in SEQ ID NO:8, CDRH2 comprises the amino acid sequence set forth in SEQ ID NO:9, and CDRH3 comprises the amino acid sequence set forth in SEQ ID NO:10 in combination with 150 mg of abemaciclib or a pharmaceutically acceptable salt thereof wherein initial administration of the abemaciclib or the salt thereof is administered to the patient without the antibody or the antigen binding fragment thereof for at least 24 hours and the abemaciclib or the salt thereof is then administered to the patient in combination with the antibody or the antigen binding fragment thereof

(canceled)

(canceled)

(canceled)

18-60. (canceled)

The method according to 2, wherein the antibody or antigen binding fragment thereof comprises a light chain variable region (LCVR) amino acid sequence of SEQ ID NO:1 and a heavy chain variable region (HCVR) amino acid sequence of SEQ ID NO:

• 2.